- Home
- FOLD
as of 03-02-2026 3:37pm EST
Amicus Therapeutics Inc is a biotechnology company focused to develop and deliver transformative medicines for people living with rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.
| Founded: | 2002 | Country: | United States |
| Employees: | 499 | City: | PRINCETON |
| Market Cap: | 4.5B | IPO Year: | 2006 |
| Target Price: | $27.25 | AVG Volume (30 days): | 4.2M |
| Analyst Decision: | Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.09 | EPS Growth: | 50.00 |
| 52 Week Low/High: | $5.66 - $14.38 | Next Earning Date: | 05-12-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | 20.55% | Revenue Growth (next year): | 18.34% |
| P/E Ratio: | -159.39 | Index: | N/A |
| Free Cash Flow: | 29.8M | FCF Growth: | N/A |
AI-Powered FOLD Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Amicus Therapeutics Inc. (FOLD)
President and CEO
Avg Cost/Share
$14.31
Shares
75,000
Total Value
$1,073,182.50
Owned After
1,021,180
SEC Form 4
Chief People Officer
Avg Cost/Share
$14.17
Shares
25,642
Total Value
$363,380.47
Owned After
245,690
SEC Form 4
President and CEO
Avg Cost/Share
$10.86
Shares
77,926
Total Value
$846,011.41
Owned After
1,021,180
SEC Form 4
Chief People Officer
Avg Cost/Share
$11.00
Shares
25,643
Total Value
$282,073.00
Owned After
245,690
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Campbell Bradley L | FOLD | President and CEO | Jan 20, 2026 | Sell | $14.31 | 75,000 | $1,073,182.50 | 1,021,180 | |
| Clark David Michael | FOLD | Chief People Officer | Dec 19, 2025 | Sell | $14.17 | 25,642 | $363,380.47 | 245,690 | |
| Campbell Bradley L | FOLD | President and CEO | Dec 15, 2025 | Sell | $10.86 | 77,926 | $846,011.41 | 1,021,180 | |
| Clark David Michael | FOLD | Chief People Officer | Dec 15, 2025 | Sell | $11.00 | 25,643 | $282,073.00 | 245,690 |
Compare FOLD vs Leading Stocks
See how FOLD stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "FOLD Amicus Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.